Everlab's AU$65M Raise Signals New Investor Bet on AI-Preventative Health

MELBOURNE, Australia – June 16, 2026 – In a move signaling strong investor conviction in the future of preventative medicine, Australian healthtech startup Everlab has announced an oversubscribed AU$65 million Series A funding round. The capital injection, led by local venture giant Airtree Ventures, validates a model that seeks to fundamentally shift healthcare from a reactive, illness-based system to a proactive, data-driven one.

The round saw participation from a global consortium of investors, including Plural from the EU and existing US and EU backers Left Lane Capital and b2venture, underscoring the international appeal of Everlab’s ambitious vision. The funding is earmarked to enhance the company’s clinical and technological infrastructure and fuel an aggressive global expansion, starting with the highly complex UK market.

Founded in Melbourne just last year, Everlab has rapidly positioned itself as a leader in the burgeoning field of preventative health. The company's digital platform aims to solve the chronic fragmentation plaguing modern healthcare, where patient data is siloed, appointments are transactional, and insights from personal health devices often go unactioned. By integrating diagnostics, clinician access, specialist referrals, and continuous AI-driven care into a single longitudinal record, the platform offers patients a comprehensive view of their health over time.

“The existing system is fragmented, handing patients between providers and hoping the information follows,” said Marc Hermann, Co-founder and CEO of Everlab. “We built Everlab to hold the full picture, surface health blind spots and coordinate what needs to happen next—from targeted screenings to personalised health plans—helping more people live longer, healthier lives.”

A New Frontier for Healthcare Investment

The AU$65 million figure is not just a testament to Everlab's execution but also a key indicator of a broader shift in the investment landscape. Venture capital is increasingly flowing into companies that promise not just marginal improvements, but systemic change, particularly in sectors with ballooning costs like healthcare. The focus is moving toward models that can generate long-term value by reducing the lifetime cost of care for entire populations.

Investors see a massive opportunity in disrupting the $10 trillion global consumer healthcare market with proactive solutions. “The more time we spent with the Everlab team, the more convinced we became that they’re building a generational health business,” commented John Henderson, Partner at lead investor Airtree. “With a world-class product and growing at a pace we rarely see, they’re already the leader in Australia and we’re backing them to do the same globally.”

This sentiment is echoed by international backers who have seen other models fail. Carina Namih, Partner at Plural, highlighted the platform's unique strategic positioning. “Every company that has tried to own the patient journey has ended up either selling doctor time by the minute or reselling lab tests with thin margins,” she explained. “Everlab is building the layer above both: the system that interprets and coordinates your health data over time rather than capturing a single transaction. The fact that they’ve already proven their model operationally in Australia, at scale, is what convinced me this is the version that genuinely works.”

A Data-Driven Diagnosis

At the core of Everlab’s value proposition is its powerful data integration and AI engine. The platform synthesizes information from a vast network of over 1,850 health provider locations, insights from more than 30 wearable devices, and the expertise of 180+ active clinicians. This engine processes over 200,000 health reports per month, creating a rich, continuous data stream for each patient.

The results of this approach appear compelling. Having processed over 21 million biomarker test results, the company claims that more than a quarter of its members have had health risks flagged that were missed by the traditional healthcare system. Critically, for 2.5% of its 20,000 patients, these findings have revealed serious conditions, including early-stage cancers, enabling potentially life-saving early intervention.

This is the crux of the preventative model: using advanced diagnostics and AI-powered analysis to identify risk markers long before symptoms manifest. It transforms the annual physical from a brief, surface-level check into a deep, data-informed analysis. The company has already completed over 40,000 consultations, serving individuals and major corporate partners like Boston Consulting Group, BHP, and Bain & Company, who are increasingly looking to invest in the long-term health of their workforce.

The Currency of Trust in a Digital Age

As Everlab scales its operations, its greatest asset—and its greatest responsibility—is the vast trove of sensitive health data it manages. The platform’s success hinges on its ability to maintain patient trust while leveraging AI to deliver personalized care. This is a delicate balancing act that will come under increasing scrutiny with its international expansion.

“Our patient base reflects the broader Australian population, and earning their trust to hold decades of their health data is the foundation everything else runs on,” stated Dr. Steven Lu, the company’s Chief Medical Officer. This acknowledgment sits at the heart of the ethical considerations for any AI-driven health platform. The system’s AI agents are designed to ingest and interpret complex health data, automate clinical summaries, and recommend interventions, but the final word remains with clinicians and patients.

Navigating the regulatory environment is paramount. In Australia, the company must adhere to the Australian Privacy Principles. As it enters the UK, it will face the stringent requirements of the General Data Protection Regulation (GDPR) and oversight from bodies like the Care Quality Commission (CQC) and the Medicines and Healthcare products Regulatory Agency (MHRA). Building a platform that is not only effective but also transparent, secure, and compliant across multiple jurisdictions will be a key challenge and a critical determinant of its long-term viability.

With its significant new funding, Everlab is well-capitalized to tackle these challenges. The company is not just selling a product but a paradigm shift—a vision of healthcare where technology and data empower individuals and clinicians to prevent disease before it strikes. The journey from a promising Australian startup to a global force in healthcare will be complex, but the institutional backing it has garnered suggests that many believe it is a future worth investing in.